Key Drivers
- Strong Margins
- Weak FCF
- Sturdy Balance Sheet
AIAI Summary
RDY should be viewed as a transition story rather than a plain-vanilla generics name: its strong margins and low leverage can absorb lenalidomide erosion only if semaglutide and biosimilar launches quickly convert regulatory progress into real sales, otherwise the stock likely remains range-bound despite the pipeline.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Weak FCF
- •Sturdy Balance Sheet
RDY is financially resilient and highly profitable, but weak free-cash-flow conversion and a valuation that already reflects quality limit the upside.
Price Behavior
Key Price Behavior Insights:
- •Support Rebound
- •Range Resistance
- •Volatile Selloff
Over the last month, RDY has rebounded off support near $12.50 and recovered above $13.0, but repeated failures in the $13.70-$14.00 zone keep it range-bound until a clean break above $14.00.
Sharp drop from $13.72 on 2026-05-01 to $12.46 on 2026-05-12, followed by a quick rebound
Sentiment & News
Key News Insights:
- •Earnings Miss
- •Semaglutide Approval
- •U.S. Pricing فشار
Dr. Reddy's posted a mixed outlook as FY26 revenue hit a record and Canada approved its generic semaglutide, but earnings missed and U.S. generics pricing pressure weighed on results.
The stock likely stays range-bound near term as operational pressure in North America is offset by a meaningful product-approval catalyst
Similar Companies in Healthcare
Other companies in the same sector with AI ratings